News

Greg Scott, national leader of the health plans practice at Deloitte Consulting, LLP, shares how plans and providers may be able to better apply big data.

As 2015 comes to a close, a look at this year's challenges and next year's opportunities.

In this Q&A, a presenter at the upcoming ASH conference discusses new hematology payment models and the top challenges payers face in this area.

Express Scripts is partnering with Imprimis Pharmaceuticals to provide access to a low-cost alternative to Daraprim (pyrimethamine). Here's why.

A study published in the October 26th issue of the JAMA Internal Medicine journal shows that physicians don't typically reduce older patients' diabetic medications, even when the patients have low blood sugar levels.

A new joint program with the Mount Sinai Health System and Livongo Health, a consumer digital health company, is expected to help diabetics manage their disease better.

In its latest round of cancer drug approvals, the FDA last week approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC).

Managed Healthcare Executive's State of the Industry Survey findings reveal that most plans and providers are struggling with data analytics. Here are some tips.

The top 5 industry challenges facing managed care executives, according to the findings of Managed Healthcare Executive's State of the Industry Survey.

Experts say you should follow these 6 therapeutic areas.

The results of a large study of the impact of empagliflozin (Jardiance) on cardiovascular outcomes were recently published. Here are some key takeaways.

Insurers like Aetna are implementing payment models for hematologic conditions.

What are the top pharmacy challenges expected by healthcare executives in 2016 and what are they doing about it? Find out.

The healthcare industry may look back on 2015 as a "watershed year," during which the switch from volume to value solidified. But the transition isn't without its challenges.

Super clinically integrated networks can strengthen each of the independent members.

FDA approved nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of patients with metastatic renal cell carcinoma.

Here's how four plans are using the management strategy to improve quality, reduce costs.

FDA this week approved a new indication for BioThrax to prevent disease following suspected or confirmed exposure to Bacillus anthracis, the bacterium that causes anthrax disease.

A new AARP report shows that the rapid rise in cost of specialty drugs exceeds median family income.

Traveling to Orlando for ASH 2015? Make the most out of your trip by attending these presentations. View the top 10.

In FDA’s latest approval of a new medication to treat multiple myeloma, the agency approved Ninlaro capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy

Here are five ways payers could help their members become more engaged in their health and provider-recommended treatment plan.

During the first half of 2016, UnitedHealth Group will determine to what extent it can to participate in the public exchange markets in 2017. Here's what this means for the industry.

The three trends that will carry into next year.

Most idiopathic pulmonary fibrosis patients have considerably impaired lung function and gastroesophageal reflux disease is the most common co-morbidity, according to initial results from the IPF-PRO Registry.

Manufactured by Adapt Pharma, Narcan is the first FDA-approved nasal spray version of naloxone hydrochloride, a life-saving medication that can stop or reverse the effects of an opioid overdose. Up until now, naloxone has only been available in an injectable form.

Is your plan making full use of its population health management systems? To help you find out, we asked two experts to weigh in.